Matthew McManus's most recent trade in Fold Holdings inc. - Ordinary Shares - Class A was a trade of 108,808 Common Stock done . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fold Holdings inc. - Ordin... | Matthew McManus | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 108,808 | 108,808 | - | 0 | Common Stock | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,620 | 4,620 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 4,620 | 9,241 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.55 per share. | 01 Feb 2025 | 1,642 | 2,978 (0%) | 0% | 73.5 | 120,769 | Common Stock |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 21,320 | 21,320 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 15,825 | 15,825 | - | - | Performance Restricted Stock Units | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 15,818 | 15,818 | - | - | Performance Restricted Stock Units | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 7,912 | 7,912 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | McManus Matthew | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 15,902 | 15,902 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 13,861 | 13,861 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | McManus Matthew | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 7,951 | 7,951 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Matthew McManus | President - DGS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 2,888 | 2,888 | - | - | Restricted Stock Units | |
| Azenta Inc | Matthew McManus | EVP & Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 58.15 per share. | 19 Aug 2022 | 8,625 | 29,467 (0%) | 0% | 58.2 | 501,544 | COMMON |